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Abstract
Background: In response to the lack of comprehensive information about the health and economic
benefits of quitting smoking for Australians, we developed the Quit Benefits Model (QBM).
Methods: The QBM is a Markov model, programmed in TreeAge, that assesses the consequences of
quitting in terms of cases avoided of the four most common smoking-associated diseases, deaths avoided,
and quality-adjusted life-years (QALYs) and health care costs saved (in Australian dollars, A$). Quitting
outcomes can be assessed for males and females in 14 five year age-groups from 15–19 to 80–84 years.
Exponential models, based on data from large case-control and cohort studies, were developed to
estimate the decline over time after quitting in the risk of acute myocardial infarction (AMI), stroke, lung
cancer, chronic obstructive pulmonary disease (COPD), and death. Australian data for the year 2001 were
sourced for disease incidence and mortality and health care costs. Utility of life estimates were sourced
from an international registry and a meta analysis.
In this paper, outcomes are reported for simulated subjects followed up for ten years after quitting
smoking. Life-years, QALYs and costs were estimated with 0%, 3% and 5% per annum discount rates.
Summary results are presented for a group of 1,000 simulated quitters chosen at random from the
Australian population of smokers aged between 15 and 74.
Results: For every 1,000 males chosen at random from the reference population who quit smoking, there
is a an average saving in the first ten years following quitting of A$408,000 in health care costs associated
with AMI, COPD, lung cancer and stroke, and a corresponding saving of A$328,000 for every 1,000 female
quitters. The average saving per 1,000 random quitters is A$373,000. Overall 40 of these quitters will be
spared a diagnosis of AMI, COPD, lung cancer and stroke in the first ten years following quitting, with an
estimated saving of 47 life-years and 75 QALYs. Sensitivity analyses indicated that QBM predictions were
robust to variations of ± 10% in parameter estimates.
Conclusion: The QBM can answer many of the questions posed by Australian policy-makers and health
program funders about the benefits of quitting, and is a useful tool to evaluate tobacco control programs.
It can easily be re-programmed with updated information or a set of epidemiologic data from another
country.
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Background
The prevalence of cigarette smoking in Australia has
decreased markedly over the last two decades, from 35%
in 1980 to 23% in 2001[1]. Policy-makers now often
question the cost-effectiveness of proposed tobacco con-
trol activities, as well as the expected impact of current
smoking patterns on specific diseases, health care utilisa-
tion and health care costs. A number of recent analyses
have improved understanding in Australia of the potential
benefits of further reductions in smoking rates. In 2003,
Scollo outlined the economic and public policy rationale
for greater investment by Australian governments in
tobacco control. [2]. Hurley and colleagues,[3] in 2004,
modelled the potential impact of reductions in smoking
prevalence on Pharmaceutical Benefits Scheme (PBS) sub-
sidies. They predicted that a 5% reduction in Australian
smoking rates would reduce PBS spending on drugs for
smoking-related cardiovascular disease by $4.5 billion
over the following 40 years, a 17% reduction. Subse-
quently, Hurley also modelled the impact of a 5% reduc-
tion in Australian smoking rates on myocardial infarction
and stroke hospitalisations and costs [4]. Predicted cost
savings within 7 years were over $60 million.
Although these analyses interested policy-makers, they
did not provide comprehensive quantitative predictions
of the disease-specific health and health economic bene-
fits of quitting smoking in Australia. Nor could we find a
published model that could be adapted to provide such
analyses. For example, the Tobacco Policy Model, devel-
oped by Tengs and colleagues for the United States popu-
lation, predicts savings in smoking-associated mortality,
morbidity and costs [5]. However, the impact of quitting
on individual diseases is not modelled. Orme et al. devel-
oped the HECOS (health and economic consequences of
smoking) model and used data from the United Kingdom
to illustrate its capacity to evaluate smoking cessation
strategies [6]. These researchers intended that the HECOS
model would be widely accessible and modifiable for
application to other countries, but the version we sourced
could not be adapted to provide the analyses we needed.
Johansson and colleagues developed a similar model to
predict the health and economic consequences of smok-
ing cessation in Sweden, [7] but it is not available for
adaptation to other settings.
We therefore developed the Quit Benefits Model (QBM),
which we conceptualised primarily as a tool to evaluate
tobacco control programs where estimates of the number
of quitters are available. We developed the QBM with sim-
ilar rigour to that required for submissions to the Austral-
ian federal government for subsidisation of medicines,.
[8] so that policy-makers could compare the health eco-
nomic profile of a prospective tobacco control program
with that of other health programs seeking government
funding. The QBM can also be adapted to evaluate smok-
ing cessation programs in other countries, if local epide-
miologic data are available. The goals of this paper are
therefore, first, to describe in detail the methodology used
to develop the QBM, with particular emphasis on the
sources of parameter estimates. Second, we present sum-
maries of the benefits of quitting for Australian smokers.
These summaries include health care cost savings per
1000 quitters and the number of cases of four smoking-
associated diseases, deaths, life-years, and QALYs saved
per 1000 quitters
Methods
Design of the QBM
The QBM assesses the effect of quitting on an individual
smoker. The impacts on other people of a smoker quit-
ting, through decreased exposure to environmental smoke
or decreased in-utero exposure of an infant, are ignored.
The following outcomes are assessed separately for male
and female smokers and quitters, for various ages of quit-
ting smoking, with different durations of follow-up and
different discount rates for future benefits:
• Incidence of four diseases: acute myocardial infarction
(AMI), stroke, lung cancer, and chronic obstructive pul-
monary disease (COPD). These are the four most com-
mon causes of both death and morbidity attributable to
smoking in Australia. In 1996, they accounted for almost
84% of the 16,875 deaths caused by smoking, and almost
78% of the 242,138 disability-adjusted life-years (DALYs)
that were lost due to smoking [9].
￿ Total deaths, including deaths attributable to all smok-
ing-related diseases, and deaths due to the above four dis-
eases.
￿ Life expectancy.
￿ Quality-adjusted life-expectancy (QALE). Quality
adjustments to life-expectancy were made based on the
reduced utility of life associated with each of the four spec-
ified smoking-related diseases. A utility is formally
defined as the quantitative measure of the strength of a
person's preference for an outcome [10]. The utility of life
is assumed to vary between 1 (for perfect health) and 0
(for death). The QBM assumes that the utilities of life for
a healthy smoker and a healthy quitter are 1. Alternative
approaches, such as using mean population age-group
and sex specific utilities, or modeling possible temporary
reductions in utility of life associated with quitting could
be incorporated in future QBM analyses if suitable data
were available. The QBM assumes that each of the four
smoking-associated diseases has a utility less than 1, i.e.
patients prefer perfect health to the disease.Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
Page 3 of 20
(page number not for citation purposes)
￿ Direct health care costs associated with the above four
diseases. Indirect costs due to time lost from work are not
considered.
The consequences of quitting in terms of cases of the four
specified diseases and deaths avoided, and life-years
(LYs), quality-adjusted life-years (QALYs) and health care
costs saved are calculated by subtracting the expected
value of the outcome for a smoker from the expected
value of the outcome for a quitter who ceases smoking at
a given age and does not commence smoking again after
that age.
The QBM is a Markov-cycle tree model. Figure 1 shows the
cycle tree for the QBM from TreeAge Pro, the software pro-
gram that was used to analyse the model [11]. At the
beginning of the analysis period, all subjects (smokers
and quitters) are assumed to be in the health state "Well".
During each subsequent one year period (or cycle) simu-
lated subjects can either stay in the health state "Well", or,
if one of the four smoking-related illnesses is diagnosed
they move (transition) to the corresponding health state
"Stroke year 1", "Lung Cancer year 1", "AMI year 1", or
"COPD". If a subject dies, they move to the health state
"Dead". Subjects who develop COPD are assumed to
either stay in that state or die during subsequent cycles.
The model is more complex for the other three smoking-
associated diseases to reflect the fact that either the prob-
abilities of death, or costs, or both, varied between or
within subsequent cycles. Briefly, for subjects who
develop lung cancer, the probability of death in a given
year following diagnosis is dependent on the number of
years post diagnosis. This was handled in TreeAge Pro by
setting up a "tunnel variable" which counts the number of
years survived since diagnosis and is used as the index in
a look-up table for the probabilities of transitioning from
lung cancer to death. For stroke, the first 30 days after
diagnosis are associated with a higher probability of death
than the remainder of the first year, and the subsequent
annual probabilities of death depend on the number of
years since the stroke occurred. Again this was managed in
TreeAge Pro by setting up a "tunnel variable" to count the
number of years since the stroke occurred. For subjects
who have an AMI, the periods before admission to hospi-
tal (assumed to be the first 24 hours) and the first 28 days
in hospital are associated with higher probabilities of
death than subsequent periods. Beyond the first year after
an AMI occurs, the annual probability of death does not
vary with time since AMI. The data that underpinned the
model design are described in more detail in the follow-
ing sections of the Methods.
The QBM is analysed separately for smokers and quitters
to calculate the expected value for each of the outcomes
mentioned above, for males and females, for any of 14
five-year age-groups from 15–19 years to 80–84 years. The
midpoint of each age-interval is used to estimate expected
values for outcomes for each five-year age-group. A half-
cycle correction is applied to allow for the fact that transi-
tions between health states can take place at any time dur-
ing the modeled one-year intervals [12]. Project-specific
macros were developed in Excel to generate the various
outcomes from the QBM using the TreeAge Pro Interactive
Software. The results are summarized in Excel spread-
sheets.
The QBM assumes that, for quitters, the risk of the four
specified smoking-related diseases relative to smokers
declines over time. We assume that following a diagnosis
of lung cancer, stroke, AMI or COPD the probability of
death due to the disease is independent of smoking or
quitting status, but the risk of death from other causes
declines over time for quitters relative to smokers. How-
ever, the type of data available to model death probabili-
ties following a diagnosis of lung cancer or stroke differed
from that available for AMI or COPD. The approach we
took is described in detail under Probabilities of death for
people with smoking-related diseases. The QBM also
assumes that the risk of death from causes other than the
four specified smoking-related diseases is greater for
smokers than for the general population, and that, for
quitters, this excess risk declines over time. Health care
costs and health state utilities for the four specified smok-
ing-related diseases are assumed to be the same for smok-
ers and quitters.
With the QBM it is possible to undertake a time since quit-
ting analysis, where the expected value of each outcome is
calculated for defined periods of time since quitting, or an
analysis in which the expected value of each outcome is
calculated up until subjects die or reach 85 years. Note
that, even with the time since quitting analysis, in the QBM,
no subjects are followed beyond the age of 85 years. In
this paper, results are provided for a time since quitting
analysis with a ten year follow-up. The 10-year follow-up
period is long enough to show the beneficial impacts of
quitting, but is hopefully short enough to remain within
the time frame of policy-makers. Discount rates of 0%,
3% and 5% per annum were applied to life-years, QALYs
and costs. Cases of disease and deaths avoided were esti-
mated using Monte Carlo simulations and were not dis-
counted. Results were averaged over 10,000 simulations.
Model parameters
The most recent year for which key data were available
(for example, lung cancer incidence and hospitalisation
counts) was 2001, so it was used as the base year. The rates
in 2001 were assumed to apply to all future years, i.e. pos-
sible future temporal trends in disease incidence and mor-
tality were not incorporated in the model. The sources ofCost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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parameter estimates are described below, and estimates
for 50–54 year old males and females, for variables used
to calculate cases of disease, deaths and life-expectancy are
presented in Table 1.
Probabilities of smoking-related diseases
Annual age-group and sex- specific incidence probabilities
for the four specified smoking-related diseases were esti-
mated for smokers and quitters. Probabilities were ini-
TreeAge Markov cycle tree for the QBM Figure 1
TreeAge Markov cycle tree for the QBM.Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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tially obtained for the general Australian population (i.e.
for smokers, ex-smokers and never-smokers combined).
Probabilities for smokers were then estimated by adjust-
ing the population probabilities on the basis of smoking
prevalence data and disease relative risks. Probabilities for
quitters were estimated by adjusting the smokers' proba-
bilities according to functions that describe the decline in
risk of disease over time since quitting, relative to smok-
ers.
AMI
The probabilities of first-ever AMI were estimated as the
sum of the probabilities of first-ever fatal AMI (i.e. a fatal
AMI that had not been preceded by a non-fatal AMI) and
first-ever non-fatal AMI. The number of first-ever fatal
AMIs was estimated by adjusting national ischaemic heart
disease (IHD) 2001 mortality data (ICD 10 codes I20–
I25) [13] for miscoding [14] and for previous AMIs [15].
To estimate the number of first non-fatal AMIs we first
sourced data from the Australian Institute of Health and
Welfare (AIHW) National Hospital Morbidity Data-
base[16] on the number of hospital admissions for AMI in
2001–2 where the patient had a length of stay greater than
two days and was discharged alive, as Jamrozik et al. [14]
suggest that by excluding very short hospitalisations,
patients re-admitted for revascularisation procedures are
likely to be excluded. These data were then adjusted for
miscoding of hospitalisations to AMI [14] and for previ-
ous AMIs [15].
Stroke
Probabilities of first-ever stroke (of any type) were
obtained from NEMESIS, a population-based prospective
study of the incidence of stroke in a region of Melbourne





Pr(AMI in next year for a smoker) pAMI 0.0043 0.0012
Pr(AMI in next year for a quitter)* pAMI 0.0015 0.0004
Pr(Die from an AMI before hospitalisation|have first AMI) pDA1_1 0.1943 0.1744
Pr(Die in hospital from first AMI in first 28 days|have first AMI and hospitalised) pDA1_2 0.0347 0.0335
Pr(Die from AMI in remainder of first year|discharged from hospital) pDA1_3 0.0235 0.0149
Pr(Die from AMI in second year|survive first year) pDA2 0.0235 0.0149
Stroke
Pr(Stroke in next year for a smoker) pStroke 0.0026 0.0016
Pr(Stroke in next year for a quitter)* pStroke 0.0014 0.0008
Pr(Die from a stroke in first 30 days|have first stroke) pDS1_1 0.2250 0.2250
Pr(Die from stroke in first year|survive first 30 days) pDS1_2 0.1818 0.1818
Pr(Die from stroke in second year|survive first year)† pDS2 0.0833 0.0833
Lung cancer
Pr(Lung cancer in next year for a smoker) pLCa 0.0016 0.0011
Pr(Lung cancer in next year for a quitter) pLCa 0.6998 0.0006
Pr(Die from lung cancer in first year|have lung cancer pDL1 0.5930 0.5099
Pr(Die from lung cancer in second year|survive first year)† pDL2 0.4069 0.3602
COPD
Pr(COPD in next year for a smoker) pCOPD 0.0075 0.0062
Pr(COPD in next year for a quitter) pCOPD 0.0052 0.0035
Pr(Die from COPD in year|have COPD) pDC 0.0081 0.0060
MORTALITY FROM OTHER CAUSES
Pr(Die from other causes in next year for a smoker) pDie_other 0.0040 0.0029
Pr(Die from other causes in next year for a quitter) pDie_other 0.0026 0.0024
Note that Probabilities vary once smokers or quitters age into the next stratum
Pr = probability
| = conditional on
* 5 years after quitting at age 45–49 years
+ Different probabilities for subsequent yearsCost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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in 1996–97 [17]. This is the most recent population-based
study of stroke incidence in Australia. The only other Aus-
tralian study was conducted in Perth in 1989–90 [18]. The
NEMESIS study provided similar incidence estimates,
standardized for population age and sex distribution, to
recent studies in Italy, Germany and Greece [17]. The
NEMESIS study probabilities were assumed to apply to
the year 2001, as the hospitalisation rate for stroke varied
by < 1% over the subsequent years, 1997–98 to 2001–
2002[16].
Lung cancer
Australian incidence probabilities for lung cancer for
2001 were sourced from the National Cancer Statistics
Clearing House [19].
COPD
No population-based studies of the incidence of COPD in
Australia have been conducted, and there are no routine
data collections, such as exist for AMI, from which inci-
dence could be estimated. Estimates of COPD incidence
in 2003 for Australia, by age-group and sex were provided
by Dr Theo Vos (University of Queensland, personal com-
munication 24/8/2005). These estimates had been
derived for the Australian 2003 Burden of Disease study
(in progress). Vos and colleagues had originally estimated
COPD prevalence for the 1994 Victorian Burden of Dis-
ease study, from population-based respiratory function
data obtained from the Busselton health surveys. COPD
was defined as forced expiratory volume in one second
(FEV1) less than 70% of predicted, excluding those with a
doctor's diagnosis of asthma. They then used DisMod (the
precursor of DisMod II) to estimate COPD incidence in
1994. DisMod II is a software package developed by the
World Health Organisation and its collaborators for the
Global Burden of Disease 2000 study [20]. It is based on
a set of differential equations, and enables users to calcu-
late the complete epidemiology of a disease of interest
given a minimum of three input variables. Vos and col-
leagues then estimated incidence in 2003 based on the
observed changes in COPD mortality between 1994 and
2003.
We used log-linear interpolation between 1994 and 2003
to estimate the 2001 incidence for each age-and-sex-
group.
Disease risks for smokers
The above estimates represented the annual incidence
probability for the four specified smoking-related dis-
eases,  DP, for the Australian population. For AMI and
stroke, the probability of disease (in a year) for smokers,
DS, was estimated by first estimating the probability of
disease for a never-smoker, DNS, according to the follow-
ing formula:
DNS = DP/((1-pEX - pS) + pEX*RREX + pS*RRS)
Where pS is the prevalence of smokers, pEX is the preva-
lence of ex-smokers and RRS and RREX are the risks of dis-
ease for smokers and ex-smokers, respectively, relative to
never-smokers. Then:
DS = DNS* RRS
Smoking prevalence data were sourced from the Austral-
ian Bureau of Statistics 2001 National Health Survey
(NHS) [21]. Dr Mohammad Siahpush (Cancer Council
Victoria) queried the Remote Access Data Laboratory
(RADL) using SPSS to obtain counts of smokers and ex-
smokers by age-group and sex. The Australian Estimated
Resident Population for 2001 was used to calculate pro-
portions [22]. The relative risks of AMI and stroke were
sourced from the meta analyses by English et al. [23].
The above method for estimating AMI and stroke disease
risks for smokers was modified for lung cancer and
COPD. Because of the long lead times from exposure
(smoking) to development of lung cancer and COPD,
substitution of the current smoking prevalence in the
above equations to estimate DS for these diseases would
be inappropriate, and in Australia, where smoking preva-
lence has decreased over time, would lead to underestima-
tion of the proportions of these diseases attributable to
smoking. Peto et al. [24] developed a method for indirect
estimation of mortality from tobacco using published
vital statistics, and part of this method was used by Dr
Chris Stevenson from the AIHW to estimate Australian
age-group and sex specific "synthetic prevalence" in 2001
for smoking. The "synthetic prevalence", pe,can be inter-
preted as the historical smoking prevalence that gave rise
to the current lung cancer mortality (personal communi-
cation, 16/6/2005). DNS was then estimated as follows:
DNS = DP/((1 - pe + pe*RRS)
and DS was estimated as for AMI and stroke.
The relative risk of lung cancer for smokers versus never
smokers was estimated from data in the Appendix of Peto
et al. [24]. For never-smokers, the smoothed never-
smoker rates were used. It was assumed that the rates of
death from lung cancer among smokers and never smok-
ers measured in the American Cancer Society (ACS) Can-
cer Prevention Study (CPS-II) applied to the Australian
population. The relative risk of COPD for smokers was
obtained from English et al. [23] and was 9.8 for males
and females. This is a conservative estimate compared
with the estimates of 14.1 for males and 14.8 for females
obtained by averaging the relative risks for ages ≥ 50
reported in Peto et al. [24].Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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Disease risks for quitters
Stroke and AMI
For stroke and AMI, the non-linear models published in
Hurley [4] were used to estimate relative risks after smok-
ing cessation. These non-linear models were updated ver-
sions of the models developed by Lightwood and Glantz
for an analysis of the benefits of smoking cessation on
stroke and AMI hospitalisation costs in the United
States[25]. Hurley fitted non-linear models of the risks,
RR(t) of AMI and stroke for ex-smokers relative to never
smokers as a function of time, t, months since quitting.
For the QBM, these functions were transformed to express
risks for ex-smokers relative to current smokers, and are
shown by year since quitting in Table 2. Note that the orig-
inal data for fitting these models were available separately
for males and females for AMI, but for stroke, only data
for males and females combined were available.
Lung Cancer and COPD
Risk ratios for lung cancer for ex-smokers versus current
smokers for specified time-periods since quitting were
sourced from Peto et al. [26] and from Table F on the cor-
responding website. An exponential model to describe the
decrease in risk of lung cancer over time was developed,
and we assumed that this function also described the
decrease in risk of COPD. We assumed that the relative
risk, rr(t) of developing lung cancer for an ex-smoker who
ceased smoking t months ago relative to a current smoker
could be expressed as:
rr(t) = [(1- rr∞)]*e-t/τ + rr∞
where rr∞ is the relative risk of lung cancer for a never-
smoker versus a current smoker, and τ is a slope parameter
which is inversely proportional to the rate at which the
relative risk decreases with time since quitting. Due to the
paucity of data available, this model assumes that the risk
for an ex-smoker eventually becomes the same as that of a
never-smoker. The values of rr∞ were taken to be 0.03 and
0.05 respectively for males and females, as given in Peto et
al. [26]. The values of τ were estimated by fitting the fol-
lowing non-linear model to the data.
ln(rr(t)) = ln([(1- rr∞)]*e-t/τ + rr∞ + ε
The non-linear regression procedure (Levenberg-Mar-
quardt estimation method) in the SPSS statistical software
package was used. The natural logarithms of the relative
risks were weighted proportionally to the inverse of their
variances, which were estimated from the reported confi-
dence intervals for the relative risks.
The estimated values of τ were 162 (95% CI: 129 – 195)
for males, and 100 (95% CI: 61 – 139) for females. The
reported and estimated relative risks are given in Table 3.
Mortality risks
Probabilities of death for people with smoking-related diseases
AMI
The probability of dying in hospital following the first
AMI was calculated from the hospitalisation data sourced
from the AIHW[16]. The probability of dying before
reaching hospital was estimated by assuming that all first
AMI deaths occurred before reaching hospital or in hospi-
tal, on the basis that a death post discharge would be due
to a second or subsequent AMI or due to other causes.
The AMI case fatality rate, for estimation of the probability
of dying in the first year after discharge from hospital and
in subsequent years, was calculated in DisMod II. Inputs
were the AMI incidence probabilities (described above
under  Probabilities of smoking-related diseases), the
IHD-specific population mortality rates, [13] and the
remission rate (which was assumed to be zero). It was
assumed in males that 70% of case fatalities were due to
the first AMI and in females that 80% were due to the first
AMI. The AMI case fatality rates were adjusted accordingly
to provide case fatality rates due to second or subsequent
AMIs, and converted to probabilities using the formula in
Section 3. These are the probabilities of someone who has
had an AMI dying from an AMI, and were assumed to be
Table 2: Risks of AMI and stroke in quitters relative to smokers by time since quitting*
Year since quitting Estimated RR
AMI AMI Stroke
Males Females Males and Females
1 0.66 0.66 0.75
2 0.49 0.49 0.63
3 0.41 0.41 0.57
4 0.37 0.36 0.54
5 0.35 0.34 0.53
* Source: Hurley[4]Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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the same for smokers and quitters. The probabilities of
dying of causes other than AMI were then added to these
probabilities. For quitters, the risk of death from other
causes was assumed to decline over time relative to smok-
ers, according to the function described below under Mor-
tality risks (other causes).
Stroke
The probabilities of death following a stoke were based on
outcomes for two cohorts of patients enrolled in the Perth
Community Stroke Study, a population-based study in
the state of Western Australia, in 1989–90 and 1995–96.
These were the only Australian stroke survival data availa-
ble. The probability of death in the first 30 days post
stroke was 22.3% in the first cohort [27] and 22.5% in the
second, [28] so an estimate of 22% was used in the QBM.
The probabilities of death for the 1995–96 cohort were
used for the first five years post-stroke and data for the
1989–90 cohort were used for the 6–10 year post-stroke
period. The probabilities 10 years post-stroke were
applied to all subsequent years. As these studies recorded
deaths from all causes for a cohort of people (smokers,
quitters and never-smokers) who had experienced a
stroke, it was not necessary to add the probability of dying
from other causes, and the same death probabilities were
used for both smokers and quitters.
Lung cancer
The probabilities of death following a diagnosis of lung
cancer were calculated from Victorian Cancer Registry sur-
vival data, for cases diagnosed between 1994 and 1999
(data supplied by Professor Dallas English, Cancer Coun-
cil Victoria, 12/8/2005). Probabilities of death were calcu-
lated by taking a weighted average of the probabilities in
each of the relevant years of follow-up, with weights pro-
portional to the effective number at risk during each
period. Probabilities were assumed to be constant after
the first five years post-diagnosis, to overcome the insta-
bility in the data due to the small numbers of people
being followed in these years. The probabilities of death
10 years post diagnosis were applied to all subsequent
years. No data were available in the tenth year after diag-
nosis, for males and females over the age of 80, so the
probabilities of death in the tenth year were estimated by
the probabilities of death in the previous year (i.e. the
weighted average of the probabilities for years 6 to 9 inclu-
sive). The probabilities of death 10 years post diagnosis
were applied to all subsequent years. The Cancer registry
recorded deaths from all causes for a cohort of people
(smokers, quitters and never-smokers) who had been
diagnosed with lung cancer, so, as for the stroke death
probabilities, it was not necessary to add the probability
of dying from other causes, and the same death probabil-
ities were used for both smokers and quitters.
COPD
COPD case fatality rates were estimated in DisMod II
using the estimated COPD incidence for 2001 (see Prob-
abilities of smoking-related diseases, above), COPD
remission rates (assumed to be zero) and COPD-specific
population mortality rates from the AIHW GRIM books
[13] as input. The case fatality rates, which were assumed
to be the same for smokers and quitters, were converted to
probabilities and the probabilities of dying of causes
other than COPD were then added to these probabilities.
For quitters, the risk of death from other causes was
assumed to decline over time relative to smokers, accord-
ing to the function described below under Mortality risks
(other causes).
Mortality risks (other causes)
The other mortality risk data needed to analyse the QBM
are the transition probabilities from the state "well" to
"dead" for smokers and quitters. We refer to these risks as
"other causes" mortality, as the risk of dying from any of
the four specified smoking-related diseases is excluded.
We took the following approach to estimating these prob-
abilities:
￿ Age-group, sex-specific mortality probabilities for all
causes and for AMI (ICD 10 codes I20–I25), stroke (I60–
I69), lung cancer (C33, C34) and COPD (J41–J44), for
2001 for the Australian population were sourced from the
AIHW GRIM books [13].
Table 3: Risk of lung cancer in quitters relative to smokers by time since quitting
Group Years since quitting Reported RR* Estimated RR Difference
Males < 10 0.66 0.70 -0.04
10 – 19 0.42 0.35 0.07
20 – 29 0.18 0.18 0.00
≥ 30 0.08 0.10 -0.02
Females < 10 0.69 0.57 0.12
10 – 19 0.21 0.21 0.00
≥ 20 0.05 0.08 -0.03
* Source: Peto et al.[26]Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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￿ Smoker-specific mortality probabilities for the four
smoking-related diseases were estimated using the meth-
odology described under Disease risks for smokers, assum-
ing that the relative risks for mortality were the same as
the relative risks for incidence of the specified diseases and
substituting mortality probabilities for disease probabili-
ties. To calculate all causes mortality risk for smokers, we
used the same methodology, and sourced relative risks
from the American Cancer Society (ACS) Cancer Preven-
tion Study (CPS-II) data reported in Table 3 of Taylor et al.
[29] Values for age less than 50 years were applied to age-
groups 30–34 to 45–49 years. Relative risks were assumed
to be one for age less than 30 years, as no participants in
the CPS -II were younger than 30 years.
￿ The probability of a smoker dying of "other causes" (i.e.
not AMI, stroke, lung cancer or COPD) was estimated by
subtracting the four disease-specific mortality probabili-
ties for smokers from the all causes mortality probability
for smokers.
￿ Quitters' mortality risks for other causes were estimated
by developing a function describing the decline in risk of
death from all causes for quitters relative to smokers and
applying the function to the probability of death from
other causes for smokers. Data for the decline in all causes
mortality risk for quitters relative to smokers were also
sourced from the ACS CPS-II data reported by Taylor et al.
[29]. Relative risks were given for five age-groups for males
and females separately, and for four time-periods since
quitting: 3–5 years, 6–10 years, 11–15 years and > 16
years. For the first three time periods the relative risk was
taken to apply at the midpoints of the intervals, i.e. at 4, 8
and 13 years respectively. For the final interval, the rela-
tive risk was taken to apply at 20 years. As for lung cancer,
it was assumed that the relative risk, rr(t) of dying for an
ex-smoker who ceased smoking t months ago relative to a
current smoker could be expressed as
rr(t) = (1- rr∞)*e-t/τ + rr∞
where rr∞ is the relative risk of death for a never-smoker
versus a current smoker, and τ is a slope parameter which
is inversely proportional to the rate at which the relative
risk decreases with time since quitting. Again this model
assumes that the risk of death for an ex-smoker eventually
becomes the same as that of a never-smoker.
The relative risks and confidence intervals reported in
Table 3 in Taylor et al. [29] were first expressed relative to
never-smokers. Letting RR(t) represent the risk of death
for an ex-smoker who ceased smoking t months ago rela-
tive to a never-smoker, then
RR(t) = rr(t) *RR0
where RR0 = RR(0), the relative risk of death for a current
smoker versus a never-smoker. By definition, RR0 = 1/rr∞.
Thus
RR(t) = (RR0-1)*e-t/τ + 1
The values of τ were estimated by fitting the non-linear
model
ln(RR(t)) = ln((RR0-1)*e-t/τ + 1) + ε
to the data in Table 3 in Taylor et al. [29]. The parameters
RR0 and τ were allowed to assume separate values for each
sex and age-group, and the regression errors (ε) were
assumed to be independent. Again, the regression analy-
ses were carried out using the non-linear regression proce-
dure in the SPSS statistical software package, using the
Levenberg-Marquardt estimation method. The natural
logarithms of the relative risks were weighted propor-
tional to the inverse of their variances. These variances
were estimated from the reported confidence intervals for
the relative risks.
For each sex and age-group, the values of rr∞  were
obtained directly by taking the inverse of the risks for cur-
rent smokers relative to never-smokers reported in Taylor
et al. These values of rr∞ could have been estimated by
inverting the estimated parameters RR0 from the model-
fitting procedure, however it was considered that the
directly reported values would be more accurate that the
estimated values. In reality, the estimated and reported
values differed by < 3% in all cases.
The estimated values of τ and rr∞ are shown in Table 4 and
the corresponding estimated relative risks for each sex and
age-group are compared in Table 5 with the values
obtained from Table 3 in Taylor et al. [29] by dividing the
reported risks (RR) for quitters relative to never-smokers
by the reported risks for current smokers relative to never-
smokers.
Health care costs for smoking-related diseases
The health care cost estimates used in the QBM for the
four specified smoking-related diseases are summarised in
Table 6, and the sources of these estimates are described
below. All costs in the QBM are in Australian dollars, A$.
We conducted searches of the Medline database and Inter-
net to identify Australian studies of the cost per patient for
the four diseases. For AMI and COPD, no suitable Austral-
ian data could be found. Therefore, for AMI, we derived
costs from Australian Refined Diagnosis Related Group
(AR-DRG) and health service utilisation data. For COPD,
we used a Canadian estimate.Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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AMI
Hospitalisation costs were used as estimators of the AMI-
related health care costs for the first year. The AR-DRG cost
weights for the actual AR-DRGs for hospital admissions in
2001–2 for 35–64 year olds were supplied by the AIHW
for the previous study of AMI and stroke hospitalisation
cost savings associated with tobacco control by Hurley [4].
AR-DRG cost weights were available for admissions with
a primary diagnosis of AMI, with or without revascularisa-
tion through percutaneous coronary intervention (PCI) or
coronary artery bypass grafting (CABG). The AIHW report
on coronary heart disease in Australia by Mathur [30]
includes data on the proportion of 40–84 year old
patients in Perth in 1997 who received either of these cor-
onary revascularisation procedures at various time points
after their AMI (i.e. during their acute admission, or
within 30 days, 90 days and 1 year of the acute admis-
sion). These proportions and the relevant cost weights
were combined to estimate costs for "Hospital admission"
and "Remainder of year 1", separately for men and
women.
Costs for "Year 2 and later" were assumed to be ambula-
tory care costs only. It was assumed that a patient would
be prescribed one of the statin drugs plus one other drug
and would visit a general practitioner twice a year. Based
on average unit costs for these pharmaceuticals and serv-
ices, the annual cost was estimated to be A$1,400.
These estimates for AMI are conservative, as hospitalisa-
tion costs after the first year are not included. Many
patients who survive their first AMI subsequently die from
ischaemic heart disease, and in some instances would be
hospitalised before death.
Stroke
Costs were based on NEMESIS, the prospective Australian
study used as a source of stroke incidence probabilities
[17]. Costs from NEMESIS were adjusted to 2001 dollars
on the basis of the health index of the Consumer Price
Index (CPI) for Australia [31].
Dewey et al. reported a range of cost estimates derived
from NEMESIS, including first-year costs for first-ever-in-
a-lifetime stroke, and lifetime costs. For the QBM, the
direct health care cost in the first 30 days after a stroke was
estimated as the product of the proportion of incident
cases admitted to hospital (88%, From Table 1 in Dewey
et al. [32]) and mean patient-specific acute hospitalisation
costs (A$6,651 from Table 1 in Dewey et al. [32]), giving
an estimate of A$5,900 after CPI adjustment. The cost for
the remainder of Year 1 was estimated by subtracting indi-
rect costs and acute hospitalisation costs from the first-
year cost for a first-ever stroke (A$18,956), giving an esti-
mate of A$11,600 after CPI adjustment. The cost for sub-
sequent years was estimated by dividing lifetime direct
health care costs of stroke (A$41,762) by the average sur-
vival time post stroke (6.4 years assuming 79% risk of
death at 10 years and an exponential distribution for sur-
vival), and subtracting first-year costs. After price adjust-
ment this gave an estimate of A$4,500 per year for Year 2
and later.
Lung Cancer
Costs for diagnosis and first-line therapy were taken from
an Australian study by Rosenthal et al. [33] and adjusted
to 2001 prices from 1990 prices using the health index of
the CPI (as for stroke). Total lifetime costs were estimated
assuming that these initial costs represented the same pro-
portion of total costs (66.2%) as in a more recent UK
study by Oliver et al. [34]. Annual costs and terminal costs
were then estimated using the proportions from the
Oliver study.
Table 4: Model parameters* for function describing the decline in all causes mortality after quitting
Sex Age Estimated τ Asymptotic Standard Error Asymptotic 95% CI rr∞
Male < 50 63 60 -60 – 186 0.427
50 – 59 110 22 64 – 156 0.355
60 – 69 150 16 117 – 184 0.357
70 – 79 187 22 143 – 231 0.397
≥ 80 202 57 86 – 318 0.553
Female < 50 101 143 -191 – 393 0.595
50 – 59 71 31 7 – 134 0.431
60 – 69 132 22 88 – 176 0.398
70 – 79 146 21 103 – 190 0.407
≥ 80 190 52 84 – 296 0.553
* The model fitted was: ln(RR(t)) = ln((RR0-1)*e-t/ τ+ 1) + ε, where RR(t) = the risk of death for an ex-smoker who ceased smoking t months ago 
relative to a never-smoker; RR0= RR(0), the relative risk of death for a current smoker versus a never-smoker. rr∞ = the relative risk of death for a 
never-smoker versus a current smoker (By definition, RR0 = 1/rr∞). τ is a slope parameter which is inversely proportional to the rate at which the 
relative risk decreases with time since quitting.Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
Page 11 of 20
(page number not for citation purposes)
COPD
Annual costs were estimated from the Canadian results for
the Confronting COPD study[35]. This study surveyed
over 400 Canadian patients with COPD and ascertained
their health service utilisation over the 12-month period
prior to the survey. Direct health care costs were converted
to Australian dollars on the basis of Purchasing Power Par-
ities for 2001 [36].
Utilities for smoking-related diseases
For stroke, a pooled estimate from a meta analysis was
used (see below) For AMI, lung cancer and COPD, the
means of the utility scores reported in the catalogues of
preferences published by the CEA Registry [37] and more
recent publications were used as estimates of the utility of
health states in the QBM associated with the disease. The
CEA Registry, now operated by the Institute for Clinical
Research and Health Policy Studies at the Tufts-New Eng-
land Medical Center, is recognised as a standard source for
disease utility estimates [37]. This group has conducted
exhaustive literature searches for published cost-utility
studies, and have published two on-line catalogues of the
preference scores (utilities) from these studies. Phase I
covers literature published between 1976–1997, and
Phase II covers the period 1998–2001. We sourced prefer-
ence scores from these catalogues that came from studies
Table 5: Risk of all causes mortality in quitters relative to smokers by time since quitting
Sex Age Years since quitting Reported rr* Estimated rr Difference
Male < 50 3 – 5 0.55 0.67 -0.12
6 – 10 0.62 0.54 0.08
11 – 15 0.40 0.47 -0.07
≥ 16 0.41 0.44 -0.03
50 – 59 3 – 5 0.68 0.75 -0.07
6 – 10 0.80 0.61 0.19
11 – 15 0.53 0.50 0.03
≥ 16 0.40 0.42 -0.02
60 – 69 3 – 5 0.76 0.81 -0.05
6 – 10 0.78 0.68 0.10
11 – 15 0.63 0.58 0.05
≥ 16 0.44 0.48 -0.04
70 – 79 3 – 5 0.79 0.85 -0.06
6 – 10 0.83 0.75 0.08
11 – 15 0.76 0.65 0.11
≥ 16 0.52 0.56 -0.04
≥ 80 3 – 5 0.62 0.90 -0.28
6 – 10 0.86 0.82 0.04
11 – 15 0.88 0.75 0.13
≥ 16 0.66 0.68 -0.02
Female < 50 3 – 5 0.92 0.83 0.09
6 – 10 0.65 0.74 -0.09
11 – 15 0.66 0.68 -0.02
≥ 16 0.67 0.63 0.04
50 – 59 3 – 5 0.76 0.70 0.06
6 – 10 0.56 0.57 -0.01
11 – 15 0.53 0.49 0.04
≥ 16 0.41 0.45 -0.04
60 – 69 3 – 5 0.82 0.80 0.02
6 – 10 0.75 0.68 0.07
11 – 15 0.63 0.57 0.06
≥ 16 0.44 0.49 -0.05
70 – 79 3 – 5 0.63 0.82 -0.19
6 – 10 0.73 0.70 0.03
11 – 15 0.69 0.60 0.09
≥ 16 0.49 0.52 -0.03
≥ 80 3 – 5 0.91 0.89 0.02
6 – 10 0.85 0.81 0.04
11 – 15 0.81 0.74 0.07
≥ 16 0.67 0.68 -0.01
* Source: Taylor et al.[29]: rr obtained by dividing the reported risks (RR) for quitters relative to never-smokers by the reported risks for current 
smokers relative to never-smokers in each sex and age-group.Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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where preferences had been measured. Studies where the
author or clinicians had estimated utilities were not
included. Medline searches were conducted for the period
from 2002 to October 2005 to identify any more recent
studies reporting preference scores for these diseases that
would not have been included in the Phase 11 catalogue.
AMI
A utility of 0.84 was assigned to all AMI states. The mean
of 0.84 came from seven studies: five from the 1976–1997
Catalogue (range of values: 0.87–0.93) and two from the
1998–2001 Catalogue (range: 0.58–0.88).
Stroke
All stroke health states were assumed to have a utility of
0.45. This estimate was sourced from the meta-regression
of 20 articles (contributing 53 unique quality of life
weights) by Tengs and Lin [38]. The value of 0.45 was for
moderate stroke when the scale bounds were death to nor-
mal health. It is very similar to the estimate of 0.47 for
mean AQoL (Assessment of Quality of Life) score in the
Australian NEMESIS study for 266 incident cases at 2 years
post stroke [39].
Lung Cancer
A utility of 0.63 was assumed for lung cancer. This was the
mean of four estimates. One came from the 1976–1997
Harvard Catalogue of preference scores (value: 0.73), one
came from the 1998–2001 Catalogue (value:0.58), and
two were published more recently (range: 0.58–
0.62)[40,41].
COPD
A utility of 0.61 was assumed for COPD. This was the
mean of estimates from three studies, all in the 1998–
2001 Catalogue of preference scores (range: 0.38–0.74).
Sensitivity analyses
One-way sensitivity analyses were conducted by varying,
by ± 10%, the values of each of the 20 key parameters used
to calculate QALYs and total health care costs. A multi-
way sensitivity analysis was also conducted in which AMI
and stroke incidences were decreased by 10%, to reflect
population trends, and AMI and stroke survival, costs and
utilities were increased by 10% to reflect the availability of
more costly treatments, especially for AMI, that improve
survival and quality of life.
Results
The predicted life-years, QALYs and health care costs for
males and females in each five year age-group between
ages 15 and 74, who are followed for 10 years are pre-
sented in Tables 7, 8 and 9, respectively. A full set of
results in EXCEL spreadsheet format is also available from
the authors on request. Results are presented with no dis-
counting, and 3% and 5% per annum discount rates. The
data for the age-groups beyond age 74 were not included
in the summary in order to give a full ten-year follow-up
for all age-groups. The outcomes for smokers, quitters and
the difference between the two are presented. For exam-
ple, if a male aged between 50 and 54 quits smoking, the
QBM predicts that in the following 10 years he will gain
0.1 life-years and 0.1 QALYs, and the health care cost sav-
ing associated with his reduced risk of AMI, stroke, lung
cancer and COPD would be $861, the difference between
$2,477 if he had continued to smoke and $1,616 having
become a quitter (5% per annum discounting). Cost sav-
Table 6: Health care cost estimates
Costs*
Disease state Males Females
AMI
Hospital admission $10,200 $8,800
Remainder of Year 1 $3,400 $2,700
Year 2 and later $1,400 $1,400
Stroke
First 30 days $5,900
Remainder of Year 1 $11,600
Year 2 and later $4,500
Lung cancer
On diagnosis (transition costs to lung ca) $23,400
Year 1 and later $5,000
Terminal care (transition cost to death) $7,000
COPD
Annual cost $2,200
* 2001 Australian dollarsCost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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ings in the 10 years after quitting increase with the age at
quitting, as older ages are associated with higher risks of
developing the diseases under study. However, this pat-
tern is not seen with all of the disease-specific health care
costs because the QBM is a competing risks model, and
therefore a quitter, who, through quitting, is less likely to
get one of the four diseases, may be more likely to survive
long enough to be at risk of developing the most expen-
sive of the four diseases.
In Table 10, all outcomes predicted by the QBM for a 50–
54 year old male followed for 10 years are presented. As
the cumulative probabilities of disease and death cannot
be discounted, none of the results in this Table have been
discounted. The Table shows that when a man quits
smoking at this age, the cost savings associated with
avoiding an AMI or stroke are substantially higher than
the cost savings associated with avoiding COPD or lung
cancer. By quitting, the hypothetical man's probability of
being diagnosed with  one of the four smoking-associated
diseases in the following 10 years is  reduced by 40%, and
his probability of dying is reduced by 35%.
Table 11 summarises the outcomes for 1,000 quitters cho-
sen at random from a population of smokers aged
between 15 and 74 years at the time of quitting and fol-
lowed for 10 years. The reference population (see Table
12), was the estimated Australian population of smokers
in 2001 aged between 15 and 74 years of age, obtained by
multiplying the population estimates for males and
females separately by the estimated prevalence of smok-
ing in the five-year age-groups. Overall there were an esti-
mated 2.1 million male smokers and 1.6 million female
smokers in this age range. Their age distribution is given
in Table 11, and, as expected, is more heavily skewed
towards the younger ages, because of the greater popula-
Table 7: Predicted life-years for males and females after 10 years follow-up
Males
No discounting 3% pa discounting 5% pa discounting
Age-group Smoker Quitter Difference Smoker Quitter Difference Smoker Quitter Difference
15–19 10.0 10.0 0.0 8.6 8.6 0.0 7.9 7.9 0.0
20–24 9.9 10.0 0.0 8.6 8.6 0.0 7.9 7.9 0.0
25–29 9.9 9.9 0.0 8.6 8.6 0.0 7.9 7.9 0.0
30–34 9.9 9.9 0.0 8.6 8.6 0.0 7.8 7.9 0.0
35–39 9.9 9.9 0.0 8.5 8.6 0.0 7.8 7.8 0.0
40–44 9.8 9.9 0.1 8.5 8.5 0.1 7.8 7.8 0.0
45–49 9.7 9.8 0.1 8.4 8.5 0.1 7.7 7.8 0.1
50–54 9.5 9.6 0.1 8.3 8.4 0.1 7.6 7.7 0.1
55–59 9.2 9.4 0.2 8.0 8.2 0.2 7.3 7.5 0.2
60–64 8.7 9.0 0.3 7.6 7.9 0.2 7.0 7.2 0.2
65–69 8.1 8.5 0.4 7.1 7.4 0.3 6.6 6.8 0.3
70–74 7.3 7.8 0.5 6.4 6.8 0.4 6.0 6.3 0.3
Females
No discounting 3% pa discounting 5% pa discounting
Age-group Smoker Quitter Difference Smoker Quitter Difference Smoker Quitter Difference
15–19 10.0 10.0 0.0 8.6 8.6 0.0 7.9 7.9 0.0
20–24 10.0 10.0 0.0 8.6 8.6 0.0 7.9 7.9 0.0
25–29 10.0 10.0 0.0 8.6 8.6 0.0 7.9 7.9 0.0
30–34 9.9 10.0 0.0 8.6 8.6 0.0 7.9 7.9 0.0
35–39 9.9 9.9 0.0 8.6 8.6 0.0 7.9 7.9 0.0
40–44 9.9 9.9 0.0 8.6 8.6 0.0 7.8 7.9 0.0
45–49 9.8 9.9 0.0 8.5 8.5 0.0 7.8 7.8 0.0
50–54 9.7 9.8 0.1 8.4 8.5 0.1 7.7 7.8 0.1
55–59 9.5 9.7 0.1 8.3 8.4 0.1 7.6 7.7 0.1
60–64 9.2 9.4 0.2 8.0 8.2 0.2 7.4 7.5 0.1
65–69 8.7 9.0 0.3 7.6 7.9 0.2 7.0 7.2 0.2
70–74 8.0 8.4 0.4 7.0 7.4 0.3 6.5 6.8 0.3Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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tion density and increased prevalence of smoking at the
younger ages. For males, smoking prevalence rates ranged
from 31% for 15–19 year olds to 12% for 70–74 year olds,
and correspondingly from 23% to 11% in females. These
outcomes can be conceptualised as standardised measures
of the effectiveness of a quitting program.
Overall, for every 1,000 males chosen at random from the
reference population who quit smoking, there is a an aver-
age saving of A$408,000 in health care costs associated
with AMI, COPD, lung cancer and stroke, and a corre-
sponding saving of A$328,000 for every 1,000 female
quitters. This translates to an average saving of A$373,000
per 1,000 random quitters. Overall 40 of these individuals
will be spared a diagnosis of AMI, COPD, lung cancer or
stroke in the first ten years following quitting, with an esti-
mated saving of 47 life-years and 75 QALYs.
The results of the one-way sensitivity analyses are pre-
sented in Table 13. Increasing or decreasing any of the
model parameters by 10% resulted in only small changes
in the outcomes assessed in the sensitivity analyses. The
predicted QALYs were most sensitive to a change in the
utility of COPD, but a 10% decrease in the COPD utility
estimate still only produced a 3.4% decrease in QALYs
saved per 1000 random quitters over a 10 year follow-up
period. Costs were most sensitive to a change in the rate at
which a quitter's risk of lung cancer or COPD returned to
that of a smoker. A 10% increase in τ, which corresponds
to a less rapid reduction in the risk of these smoking asso-
ciated diseases, was predicted to produce a 3.4% reduc-
tion in cost savings, and a 10% decrease in τ was predicted
to produce a 4% increase in cost savings. The QBM
remained robust when a multi-way sensitivity analysis
was performed. The predicted QALY gain for 1000 ran-
dom quitters decreased by only 7.9% and the predicted
Table 8: Predicted QALYs for males and females after 10 years follow-up
Males
No discounting 3% pa discounting 5% pa discounting
Age-group Smoker Quitter Difference Smoker Quitter Difference Smoker Quitter Difference
15–19 9.9 9.9 0.0 8.6 8.6 0.0 7.9 7.9 0.0
20–24 9.8 9.9 0.0 8.5 8.6 0.0 7.8 7.8 0.0
25–29 9.8 9.8 0.0 8.5 8.5 0.0 7.8 7.8 0.0
30–34 9.8 9.8 0.1 8.5 8.5 0.0 7.7 7.8 0.0
35–39 9.7 9.8 0.1 8.4 8.5 0.1 7.7 7.8 0.0
40–44 9.7 9.8 0.1 8.4 8.5 0.1 7.7 7.8 0.1
45–49 9.5 9.7 0.1 8.3 8.4 0.1 7.6 7.7 0.1
50–54 9.3 9.5 0.2 8.1 8.2 0.2 7.4 7.5 0.1
55–59 8.9 9.2 0.3 7.7 8.0 0.2 7.1 7.3 0.2
60–64 8.4 8.8 0.4 7.3 7.6 0.3 6.7 7.0 0.3
65–69 7.7 8.2 0.5 6.8 7.2 0.4 6.3 6.6 0.3
70–74 6.8 7.4 0.6 6.1 6.5 0.5 5.6 6.0 0.4
Females
No discounting 3% pa discounting 5% pa discounting
Age-group Smoker Quitter Difference Smoker Quitter Difference Smoker Quitter Difference
15–19 10.0 10.0 0.0 8.6 8.6 0.0 7.9 7.9 0.0
20–24 9.9 10.0 0.0 8.6 8.6 0.0 7.9 7.9 0.0
25–29 9.9 9.9 0.0 8.5 8.6 0.0 7.8 7.8 0.0
30–34 9.8 9.9 0.1 8.5 8.5 0.0 7.8 7.8 0.0
35–39 9.8 9.9 0.0 8.5 8.5 0.0 7.8 7.8 0.0
40–44 9.8 9.9 0.1 8.5 8.5 0.0 7.8 7.8 0.0
45–49 9.7 9.8 0.1 8.4 8.5 0.1 7.7 7.7 0.1
50–54 9.5 9.7 0.1 8.3 8.4 0.1 7.6 7.7 0.1
55–59 9.3 9.5 0.2 8.1 8.3 0.2 7.4 7.6 0.1
60–64 9.0 9.2 0.3 7.8 8.0 0.2 7.2 7.4 0.2
65–69 8.4 8.8 0.4 7.4 7.7 0.3 6.8 7.0 0.3
70–74 7.6 8.2 0.5 6.7 7.2 0.4 6.2 6.6 0.4Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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costs increased by only 2.4% when AMI and stroke risks
were both decreased by 10%, and AMI and stroke survival
probabilities, costs and utilities were all increased by 10%.
Discussion
The QBM predicts that the benefits of quitting smoking
are substantial in the subsequent 10-year period. For every
1000 quitters, randomly selected from the Australian
smoker population, savings of almost A$400,000 in
health care costs, and prevention of 40 cases of the four
most common smoking-associated diseases and 18 deaths
can be expected. Sensitivity analyses indicated that these
predictions are robust to plausible variations in the model
parameters.
The validity of a model such as the QBM is dependent on,
first, how well the model structure represents the out-
comes of smoking and quitting in real life, and, second,
on the accuracy of the model parameters. In developing
the QBM, when assumptions about model structure or
choices about data sources were needed, we took the most
conservative course, i.e. we chose to under-estimate the
adverse health and health care cost consequences of
smoking and to under-estimate the benefits of quitting. In
relation to disease incidence, health care costs and quality
of life, the QBM considers only four of the hundreds of
smoking-related diseases, [42] making the model conserv-
ative with respect to cost savings and QALYs, although
these four diseases do account for over 80% of morbidity
(and mortality) associated with smoking. Furthermore we
only modelled the incidences and costs associated with
Table 9: Predicted health care costs* for males and females after 10 years follow-up.
Males
No discounting 3% pa discounting 5% pa discounting
Age-group Smoker Quitter Difference Smoker Quitter Difference Smoker Quitter Difference
15–19 $268 $178 $90 $215 $144 $72 $187 $125 $62
20–24 647 $487 $160 $529 $400 $128 $465 $353 $112
25–29 $811 $635 $176 $668 $527 $142 $591 $468 $123
30–34 $905 $650 $255 $742 $536 $206 $654 $474 $179
35–39 $1,055 $730 $325 $873 $609 $264 $775 $543 $231
40–44 $1,353 $823 $530 $1,112 $682 $430 $982 $606 $376
45–49 $2,211 $1,378 $833 $1,826 $1,147 $679 $1,618 $1,022 $596
50–54 $3,355 $2,160 $1,195 $2,786 $1,808 $978 $2,477 $1,616 $861
55–59 $4,457 $2,984 $1,474 $3,731 $2,516 $1,215 $3,335 $2,260 $1,075
60–64 $5,384 $3,715 $1,669 $4,532 $3,150 $1,382 $4,065 $2,840 $1,226
65–69 $6,363 $4,514 $1,848 $5,377 $3,842 $1,535 $4,836 $3,472 $1,364
70–74 $7,595 $5,530 $2,066 $6,469 $4,734 $1,735 $5,846 $4,293 $1,553
Females
No discounting 3% pa discounting 5% pa discounting
Age-group Smoker Quitter Difference Smoker Quitter Difference Smoker Quitter Difference
15–19 $73 $38 $35 $57 $30 $27 $49 $26 $23
20–24 $333 $192 $141 $269 $156 $113 $234 $137 $98
25–29 $681 $435 $246 $560 $361 $199 $494 $320 $174
30–34 $890 $606 $284 $736 $505 $231 $652 $450 $202
35–39 $826 $580 $247 $685 $485 $200 $608 $434 $175
40–44 $958 $564 $393 $784 $467 $317 $690 $413 $276
45–49 $1,510 $932 $578 $1,249 $780 $469 $1,107 $697 $410
50–54 $2,080 $1,264 $815 $1,724 $1,060 $664 $1,531 $949 $582
55–59 $2,739 $1,669 $1,070 $2,284 $1,409 $875 $2,036 $1,266 $770
60–64 $3,562 $2,193 $1,369 $2,979 $1,854 $1,125 $2,660 $1,667 $993
65–69 $4,342 $2,769 $1,573 $3,649 $2,352 $1,296 $3,270 $2,123 $1,147
70–74 $5,429 $3,489 $1,940 $4,565 $2,956 $1,609 $4,091 $2,662 $1,429
* 2001 Australian dollarsCost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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Table 10: Predicted outcomes for a male aged between 50–54 years after 10 years follow-up.*
Outcome Smoker Quitter Difference
Life-years 9.5 9.6 0.1
QALYs 9.3 9.5 0.2
Health care costs† avoided
AMI costs $783 $340 $443
COPD costs $875 $706 $169
Lung Ca costs $861 $617 $244
Stroke costs $837 $498 $339
Total costs $3,355 $2,160 $1,195
Cumulative probability of disease
AMI 0.058 0.024 0.034
COPD 0.089 0.065 0.025
Lung Ca 0.025 0.016 0.009
Stroke 0.037 0.021 0.015
Any of the above 4 diseases 0.209 0.126 0.083
Cumulative probability of death
AMI 0.017 0.006 0.011
COPD 0.006 0.004 0.002
Lung Ca 0.016 0.011 0.005
Stroke 0.017 0.010 0.007
Any of the above 4 diseases 0.057 0.031 0.026
Causes other than the above 0.058 0.044 0.014
Total deaths 0.115 0.075 0.04
* No discounting
† In 2001 Australian dollars
Table 11: Outcomes predicted by the QBM for 1,000 quitters*
Category of benefit Per 1,000 Males Per 1,000 Females Per 1,000 Individuals
Life-years saved 57 35 47
QALYs saved 85 62 75
Health care costs† avoided
AMI costs $131 k $48 k $95 k
COPD costs $86 k $102 k $93 k
Lung Ca costs $71 k $71 k $71 k
Stroke costs $119 k $107 k $114 k
Total costs $408 k $328 k $373 k
Cases of disease avoided
AMI 14 6 11
COPD 18 20 19
Lung Ca 3 3 3
Stroke 8 7 8
Any of the above 4 diseases& 43 37 40
Deaths avoided
AMI^ 6 2 4
COPD^ 2 1 1
Lung Ca^ 2 2 2
Stroke^ 3 4 3
Any of the above 4 
diseases^
1 291 1
Causes other than the above 9 5 7
Total deaths 21 14 18
* Outcomes predicted by the QBM for 1,000 quitters chosen at random from the population of smokers aged between 15 and 74 years at the time 
of quitting and followed for 10 years. Life-years, QALYs and costs discounted at 5% per annum; cases avoided and deaths not discounted.
† In 2001 Australian dollars
&Cases and deaths have been rounded to the nearest integer and hence the total presented may not equal the sum of the components
^ These are deaths for people with these specific diseasesCost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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the first of these four smoking-related diseases which
occurred in an individual [12]. This is conservative, as
people who have had an AMI, for example, might also
subsequently have a stroke, COPD or lung cancer. How-
ever the mortality rates following a diagnosis of one of the
four diseases did include deaths from any other causes.
The QBM only considers the impact of quitting on the
smoker. This is also conservative, because smoking
adversely affects others, in particular by increasing the risk
of coronary heart disease in those exposed to environ-
mental tobacco smoke [43] and increasing the risk of a
pregnant woman who smokes having a low-birth-weight
infant. Quitting smoking can reduce these risks, [44,45]
but this was not incorporated in the QBM.
The most important parameters in the QBM are the expo-
nential models describing the decline after quitting in the
risk of the four smoking-associated diseases and other
causes mortality. These models were all based on relative
risks from studies involving very large numbers of sub-
jects. For AMI and stroke, the models were previously
developed by one of us (SH) [4] and were based on rela-
tive risks from all available published studies that met
specified criteria. Relative risks for AMI were sourced from
four case-control studies with more than 8000 cases and
more than 16,000 controls, [46-49] and one cohort study
involving almost 1000 cases and over 120,000 subjects
[50]. For stroke, relative risks came from two cohort stud-
ies with over 600 cases and more than 120,000 sub-
jects[51,52]. For lung cancer and COPD, the model was
based on relative risks from a lung cancer case-control
study with more than 600 cases and more than 2000 con-
trols [26]. The mortality model was based on the ACS CPS
II study of 1.2 million people [29].
The model structure and data sources in relation to mor-
tality are also important aspects of the QBM. Mortality
rates for the four smoking-associated diseases, were based
on case fatality data from a variety of sources. To estimate
the other causes mortality rates, cause-specific Australian
population mortality rates for these four conditions were
subtracted from the Australian all causes mortality rates.
To estimate the other causes mortality rates for quitters we
assumed that the decline in risk for quitters relative to
smokers could be estimated by the function estimating
the decline in risk for all causes mortality. If this decline in
risk has been overestimated, we would have underesti-
mated the number of quitters who would die of other
causes and hence overestimated the benefit of quitting
with respect to other causes mortality. However we would
have correspondingly underestimated the benefit of quit-
ting with respect to the incidence of the four smoking-
related diseases and their health care costs, as the quitters
would be at greater risk of these diseases through their
reduced risk of death from other causes. This highlights the
"competing risk" aspect of the model.
The QBM parameter estimates for disease probability, case
fatality, disease cost and disease utility parameter esti-
mates were based on the best available data. With the
exception of COPD, the disease probability and case fatal-
ity data came either from Australian population-based
studies or routine data collections, and the parameter esti-
mates should therefore be reasonably accurate. The COPD
incidence and fatality data were derived from Australian
data using modelling and are therefore inherently less reli-
able. However, better estimates are unlikely to be availa-
ble without a large scale prospective study because of the
typically insidious onset of COPD.
Of the health care cost estimates, the stroke data came
from the most reliable source, a comprehensive, prospec-
tive, population-based study[32]. The AMI and lung can-
cer health care cost estimates were both based on
Australian hospitalisation data, and are therefore under-
estimates. There were no Australian data on the costs of
managing patients with COPD, so data from the Cana-
Table 12: Age-distribution of reference population of smokers
Age-group Males Females Individuals
15–19 10.2% 9.4% 9.9%
20–24 11.9% 11.5% 11.7%
25–29 12.6% 12.7% 12.6%
30–34 12.6% 12.7% 12.6%
35–39 12.6% 11.8% 12.2%
40–44 10.6% 12.7% 11.5%
45–49 8.5% 8.3% 8.4%
50–54 7.5% 8.1% 7.8%
55–59 5.9% 4.8% 5.4%
60–64 3.8% 4.1% 3.9%
65–69 2.1% 1.7% 1.9%
70–74 1.8% 2.3% 2.0%Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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dian arm of an international study of COPD were
used,[35] as Canada has a similar health care system to
Australia. The disease utility estimates for lung cancer,
stroke and AMI came from an international database and
the stroke utility estimate came from a meta analysis.
So, in summary, the QBM under-estimates the benefits of
quitting, as the model only considers the impact of quit-
ting on a sub-set of the adverse health effects of smoking
and the assumptions underpinning the parameter esti-
mates were mostly conservative.
In this paper we have used the QBM to produce summa-
ries of the benefits of quitting for an individual and for a
randomly selected cohort of 1000 quitters. The model is
also a tool that can be easily used to evaluate the conse-
quences and cost-effectiveness of quitting programs. To
estimate the impact of a quitting program on a particular
outcome, such as QALYs, the number of quitters for each
age-group and sex category is simply multiplied by the
predicted difference between smokers and quitters for that
outcome, and the products are summed over all age-sex
categories. The QBM can also easily be adapted to incor-
porate different epidemiologic data. Key input tables for
the QBM can be stored in a set of linked EXCEL spread-
sheets, and imported into the TreeAge model to form a
package. These input tables can be readily updated from
the base year of 2001, for example, when more recent data
becomes available. Similarly, a set of incidence, mortality
and cost data for a different population could be input to
obtain predictions of the benefits of quitting for that pop-
ulation.
The QBM also has a variety of other potential applica-
tions. For example, one of the major current challenges for
tobacco control is the differential in smoking rates associ-
ated with socio-economic status. In Australia, for exam-
ple, people in the occupation category regarded as having
the lowest socioeconomic status are almost three time
more likely to smoke than those in the highest socioeco-
nomic occupation category[1]. The QBM could be used to
compare the cost-effectiveness of tobacco control pro-
grams targeted at smokers of low socio-economic status
with population-based programs.
Conclusion
There were sufficient good quality data available for us to
develop a comprehensive model of the health and health
economic consequences of quitting smoking for Austral-
ians. The QBM can answer many of the questions posed
by Australian policy-makers and health-care funders and
will be a useful tool to evaluate tobacco control programs.
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Table 13: One-way sensitivity analyses for QALYs and total health care costs
Parameter changed % Change in outcome given a 10% increase in 
relevant parameter
% Change in outcome given a 10% decrease in 
relevant parameter
QALYs Costs QALYs Costs
τ for AMI and Stroke -1.0% -1.1% 1.0% 1.1%
τ for lung cancer and COPD -2.4% -3.4% 2.8% 4.0%
τ for other cause mortality -1.9% 0.1% 2.2% -0.1%
Incidence AMI 1.7% 2.1% -1.7% -2.2%
Incidence Stroke 1.9% 2.8% -1.9% -2.8%
Incidence Lung Cancer 0.6% 1.8% -0.6% -1.8%
Incidence COPD 2.1% 2.0% -2.1% -2.0%
Mortality AMI 1.1% -1.1% -1.2% 1.1%
Mortality Stroke 0.4% -1.2% -0.5% 1.2%
Mortality Lung Cancer 0.2% -0.2% -0.2% 0.2%
Mortality COPD 0.2% -0.2% -0.2% 0.2%
Mortality Other Causes 2.3% -0.7% -2.3% 0.7%
Costs AMI 2.5% -2.5%
Costs Stroke 3.1% -3.1%
Costs Lung Cancer 1.9% -1.9%
Costs COPD 2.5% -2.5%
Utility AMI -2.2% 2.2%
Utility Stroke -0.8% 0.8%
Utility Lung Cancer -0.2% 0.2%
Utility COPD -3.4% 3.4%Cost Effectiveness and Resource Allocation 2007, 5:2 http://www.resource-allocation.com/content/5/1/2
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